C
Charles D. Blanke
Researcher at University of British Columbia
Publications - 106
Citations - 17049
Charles D. Blanke is an academic researcher from University of British Columbia. The author has contributed to research in topics: Imatinib mesylate & Medicine. The author has an hindex of 33, co-authored 87 publications receiving 16100 citations. Previous affiliations of Charles D. Blanke include University of Michigan & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database
Winson Y. Cheung,Q. Shi,Michael J. O'Connell,James Cassidy,Charles D. Blanke,David J. Kerr,Jeffrey P. Meyers,Eric Van Cutsem,Steven R. Alberts,Greg Yothers,Daniel J. Sargent +10 more
TL;DR: Sex is a modest independent prognostic marker for patients with early-stage colon cancer, particularly in older patients, and is not a predictive factor of treatment efficacy.
Journal ArticleDOI
Pain and Emotional Well-Being Outcomes in Southwest Oncology Group–Directed Intergroup Trial S0205: A Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine As First-Line Therapy in Patients With Advanced Pancreas Cancer
Carol M. Moinpour,Nancy L. Vaught,Bryan Goldman,Mary W. Redman,Philip A. Philip,Barbara Millwood,Scott M. Lippman,Thomas E. Seay,Patrick J. Flynn,Eileen M. O'Reilly,Kendrith M. Rowland,Ralph Wong,Jacqueline Benedetti,Charles D. Blanke +13 more
TL;DR: Improvements were similar in both treatment arms, suggesting that the addition of cetuximab did not contribute to improvement in these patient-reported health-related quality of life outcomes.
Journal ArticleDOI
Epidemiology of GIST
Journal ArticleDOI
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
Justin C. Brown,Sui Zhang,Fang-Shu Ou,Alan P. Venook,Donna Niedzwiecki,Heinz-Josef Lenz,Federico Innocenti,Bert H. O'Neil,James E. Shaw,Blase N. Polite,Crystal S. Denlinger,James N. Atkins,Richard M. Goldberg,Kimmie Ng,Robert J. Mayer,Charles D. Blanke,Eileen M. O'Reilly,Charles S. Fuchs,Jeffrey A. Meyerhardt +18 more
TL;DR: Diabetes is associated with an increased risk of mortality and tumor progression in patients with advanced or metastatic CRC and patients with diabetes tolerate first-line treatment with chemotherapy and monoclonal antibodies similarly to patients without diabetes.
Journal ArticleDOI
Combined modality therapy in non-small cell lung cancer
TL;DR: Better staging systems and definitions of biologic prognostic factors may help determine the optimal therapy for locally advanced non-small cell lung cancer patients.